Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Xeris Biopharma Holdings Q4 GAAP EPS $(0.10), Inline, Sales $44.39M Beat $43.55M Estimate

Author: Benzinga Newsdesk | March 06, 2024 08:04am

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $44.39 million which beat the analyst consensus estimate of $43.55 million by 1.93 percent. This is a 33.93 percent increase over sales of $33.14 million the same period last year.

Posted In: XERS